CD10 (CALLA, common acute lymphoblastic leukemia antigen, neutral endopeptidase-24.11, EC 3.4.24.11, NEP, encephalokinase, neprilysin)

CD10 is a 94 kDa zinc-dependent cell membrane metalloprotein which participates in the postsecretory processing of neuropeptides5, inactivating inflammatory and vasoactive peptides7. It is widely distributed in kidney, liver, small intestines, placenta, choroid plexus, brain, gonads, adrenal cortex and leucocytes5. CD10 is a marker for germinal centre cells and their derivative lymphomas4.

Previous antibodies were effective on fresh-frozen tissue only. The clone 56C6 works on paraffin-embedded tissue after antigen retrieval2,6.

Immunohistochemical expression

CD10 is not lineage-specific:

 

 

bcl-6

CD10

 

Follicular hyperplasia

19/1920

19/1920

Nodal follicular lymphoma

28/2820

22/281, 36/3920

Splenic follicular lymphoma

6/720

4/1120

MALT lymphoma

0/1720

0/2420

Mantle cell lymphoma

0/1820

0/1920

Splenic marginal zone lymphoma

0/1020

0/1320

Diffuse large B cell lymphoma

39/4720

21/5420

10 cases had evidence of previous follicular lymphoma: all but one were positive for both bcl-6 and CD1020. Of 44 DLBCL, NOS20:

 

CD10+

CD10-

bcl-6+

11

1

bcl-6-

21

11

Burkitt lymphoma

17/1720

20/2020

NLPHD

11/1320

0/1620

Classical HD

4/820

0/1320

     

 

 

vulva

vagina

uterine cervix

squamous epithelium

4/117

2/37

18/437

squamous metaplasia

 

 

4/57

eccrine glands

1/37

 

 

apocrine glands

3/47

 

 

sebaceous glands

5/57

 

 

hair follicles

5/57

 

 

condyloma accuminata

0/27

 

 

ectopic breast tissue

0/27

 

 

endocervical stroma

 

 

1/413

endocervical glands

 

 

0/397

tunnel clusters

 

 

0/37

adenosis

 

0/27

 

microglandular hyperplasia

 

 

0/37

hidradenoma papilliferum

0/47

 

 

CIN

 

 

4/137

squamous cell carcinoma

0/47

1/27

4/87

basaloid carcinoma

2/27

 

 

verrucous carcinoma

1/17

 

 

basal cell carcinoma

2/27

 

 

adenocarcinoma

 

0/17

0/147

clear cell adenocarcinoma, DES related

 

0/27

 

neuroendocrine carcinoma

 

 

0/27

mesonephric remnants

 

 

7/77

mesonephric hyperplasia

 

 

6/67

mesonephric adenocarcinoma

 

 

5/57, 1/1

malignant melanoma

2/27

 

 

 

proliferative endometrium

5/5, 39/397

secretory endometrium

5/5, 10/107

pregnancy (Arias-Stella)

10/107

decidualised endometrial stroma

negative or weakly positive8

atrophic endometrium

3/3, 9/97

hyperplasia

7/77

adenomyosis

8/87

endometriosis

19/197, 22/2513

endometrioid adenocarcinoma

1/167

adenocarcinoma with squamous metaplasia

4/67

mucinous adenocarcinoma

0/67

serous papillary adenocarcinoma

1/107

clear cell carcinoma

0/47

undifferentiated endometrial carcinoma

1/6

atypical polypoid adenomyoma

2/27

endometrial stromal nodule

1/1

low-grade endometrial stromal sarcoma

13/13

high-grade endometrial stromal sarcoma

4/6

mixed endometrial stromal-smooth muscle tumour

1/1

endometrial stromal neoplasm, NOS

4/47, 5/511

myometrium

negative8

leiomyoma

3/10, 0/67, 8/128

leiomyosarcoma

3/5, 0/37, 4/88

adult granulosa cell tumour

1/10

carcinosarcoma

3/47

uterine carcinosarcoma with endometrial stromal component

1/1

uterine mesenchymal tumour with sex cord-like elements (type 2)

1/1

adenomatoid tumour

0/37

placental chorionic stromal cells

positive8

cytotrophoblast

15/157, negative8

syncytiotrophoblast

15/157, positive on apical surface8

intermediate trophoblast

15/157

exaggerated placental site

3/37

placental site nodule

2/27

partial mole

3/37

complete mole

4/47

choriocarcinoma

2/27

placental site trophoblastic tumour

3/37

   

Fallopian tube:

normal mucosa

1/227

Walthard's rests

0/27

Epoophoron

12/137

FATWO

10/107

Adenocarcinoma

10/107

Ovary:

surface epithelium/inclusion cysts

0/67

oocytes

0/57

granulosa cells

0/57

thecal cells

0/57

rete ovarii

15/157

cyst of rete ovarii

1/27

serous cystadeno(fibro)ma

1/67

serous borderline tumour

0/47

serous carcinoma

1/117

mucinous cystadeno(fibro)ma

0/27

mucinous borderline tumour

0/67

mucinous carcinoma

1/37

endometrial borderline tumour

2/37

endometrioid carcinoma

0/57

carcinosarcoma

0/27

clear cell carcinoma

0/97

Brenner tumour

1/27

transitional cell carcinoma

0/27

Sertoli-Leydig tumour

4/57

adult type granulosa cell tumour

1/37

juvenile type granulosa cell tumour

0/17

sex cord tumour with annular tubules

0/17

steroid cell tumour

0/17

small cell carcinoma, hypercalcaemic

0/17

struma ovarii

0/27

carcinoid

1/27

dysgerminoma

1/27

embryonal carcinoma

0/27

yolk sac tumour

2/27

choriocarcinoma

1/17

breast carcinoma

0/27

gastric carcinoma (Krukenberg tumour)

0/27

colorectal carcinoma

3/37

renal carcinoma

3/37

carcinoid

1/27

malignant melanoma

2/27

   

renal cell carcinoma

41/4611, 2/212, see subtypes, 46/5426

transitional cell carcinoma

13/2411

prostatic adenocarcinoma

11/1811

pancreatic adenocarcinoma

7/1411

rhabdomyosarcoma

3/511

Schwannoma

5/1111

malignant melanoma

12/3011

 

 

CD10 expression by melanomas is associated with tumour progression17.

Diagnostic utility

References

1 Kaufmann, O. Flath, B. Spath-Schwalbe, E. Possinger, K. Dietel, M. Immunohistochemical detection of CD10 with monoclonal antibody 56C6 on paraffin sections. Am J Clin Pathol 1999;111:117-22. Positivity seen in 22 of 28 cases.

2 Delsol G, New antibodies and new applications of old antibodies in the diagnosis of hematolymphoid neoplasms. In Immunohistochemistry Long Course, Nice, October 18-23, 1998.

3 McCluggage, W. G., Sumathi, V. P., Maxwell, P. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. Histopathology 2001;39:273-278.

4 de Leval, L., Ferry, J. A., Falini, B., Shipp, M., Harris, N. L. Expression of bcl-6 and CD10 in primary mediastinal large B-cell lymphoma: evidence for derivation from germinal center B cells? Am J Surg Path 2001;25:1277-1282.

5 Borscheri, N., Roessner, A., Rocken, C. Canalicular immunostaining of neprilysin (CD10) as a diagnostic marker for hepatocellular carcinomas. Am J Surg Pathol 2001;25:1297-1303.

6 Leong A S-Y, Cooper K and Leong FJ W-M. Manual of diagnostic antibodies for immunohistology. 2nd edition, 2003

7 Ordi, J., Romagosa, C., Tavassoli, F.A., Nogales, F., Palacin, A., Condom, E., Torne, A. and Cardesa, A. CD10 Expression in Epithelial Tissues and Tumors of the Gynecologic Tract: A Useful Marker in the Diagnosis of Mesonephric, Trophoblastic, and Clear Cell Tumors. Am J Surg Pathol 2003;27:178-86.

8 Toki, T., Shimizu, M., Takagi, Y., Ashida, T. and Konishi, I. CD10 is a marker for normal and neoplastic endometrial stromal cells. Int J Gynecol Pathol 2002;21:41-7.

9 Ordi, J., Nogales, F.F., Palacin, A., Marquez, M., Pahisa, J., Vanrell, J.A. and Cardesa, A. Mesonephric adenocarcinoma of the uterine corpus: CD10 expression as evidence of mesonephric differentiation. Am J Surg Pathol 2001;25:1540-5.

10 Avery, A.K., Beckstead, J., Renshaw, A.A. and Corless, C.L. Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol 2000;24:203-10.

11 Chu, P. and Arber, D.A. Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Frequent expression in renal cell carcinoma and endometrial stromal sarcoma. Am J Clin Pathol 2000;113:374-82.

12 Ambrosiani, L., Declich, P., Bellone, S., Tavani, E., Pacilli, P., Guarneri, A., Rovellini, P. and Bianchi, A. Thyroid metastases from renal clear cell carcinoma: a cyto-histological study of two cases. Adv Clin Path 2001;5:11-6.

13 Sumathi, V.P. and McCluggage, W.G. CD10 is useful in demonstrating endometrial stroma at ectopic sites and in confirming a diagnosis of endometriosis. J Clin Pathol 2002;55:391-2.

14 Afi AM, Tan LC, Werness BA. The diagnostic utility of CD10 in evaluating endometrial lesions. Lab Invest 2002;82:189A-190A.

15 Perunovic B, Rollason TP. CD10 is not a reliable tool for identification of early myometrial invaison in endometrial adenocarcinoma. Histopathology 2003;43:401-403.

16 Groisman, G. M., M. Amar, et al. (2002). "CD10: a valuable tool for the light microscopic diagnosis of microvillous inclusion disease (familial microvillous atrophy)." Am J Surg Pathol 26(7): 902-7.

17 Bilalovic, N., B. Sandstad, et al. (2004). "CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression." Mod Pathol 17(10): 1251-8.

18 Pan, C. C., P. C. Chen, et al. (2004). "The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: an immunohistochemical analysis of 328 cases." Histopathology 45(5): 452-9.

19 Langner, C., M. Ratschek, et al. (2004). "CD10 is a diagnostic and prognostic marker in renal malignancies." Histopathology 45(5): 460-7.

20 Dogan A, Bagdi E, Munson P, et al. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 2000; 24:846-52

21 Wang HY,Mills SE. KIT and RCC are useful in distinguishing chromophobe renal cell carcinoma from the granular variant of clear cell renal cell carcinoma. Am J Surg Pathol 2005; 29:640-6

22 Makretsov NA, Hayes M, Carter BA, et al. Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Mod Pathol 2007; 20:84-89

23 Huang WB, Zhou XJ, Chen JY, et al. CD10-positive stromal cells in gastric carcinoma: correlation with invasion and metastasis. Jpn J Clin Oncol 2005; 35:245-50

24 Tse GM, Tsang AK, Putti TC, et al. Stromal CD10 expression in mammary fibroadenomas and phyllodes tumours. J Clin Pathol 2005; 58:185-9

25 Lin F, Zhang PL, Yang XJ, et al. Human kidney injury molecule-1 (hKIM-1): a useful immunohistochemical marker for diagnosing renal cell carcinoma and ovarian clear cell carcinoma. Am J Surg Pathol 2007; 31:371-81

26 Ingold B, Wild PJ, Nocito A, et al. Renal cell carcinoma marker reliably discriminates central nervous system haemangioblastoma from brain metastases of renal cell carcinoma. Histopathology 2008; 52:674-81

 

This page last revised 17.5.2008.

©SMUHT/PW Bishop